Abrogation of transforming growth factor-beta signaling in pancreatic cancer

Xia Lin1, Xin-Hua Feng

  • 1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Room 131D, Houston, Texas 77030, USA. xialin@bcm.tmc.edu

World Journal of Surgery
|February 12, 2005
PubMed

Insights

Transforming growth factor-beta (TGFbeta) inhibits cell growth. Loss of TGFbeta signaling contributes to pancreatic cancer progression by enabling uncontrolled cell proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Transforming growth factor-beta (TGFbeta) is a key regulator of cell growth, acting as a potent inhibitor for many cell types by arresting cell cycle progression.
  • Loss of responsiveness to TGFbeta signaling is a critical event in tumorigenesis, promoting uncontrolled cell proliferation and tumor progression.
  • The TGFbeta signaling pathway is frequently inactivated in pancreatic cancer, highlighting its role in this disease.

Purpose of the Study:

  • To review recent research on the role of TGFbeta signaling in pancreatic cancer.
  • To elucidate the functional connection between TGFbeta's growth inhibitory activity and Smad-mediated tumor suppression.
  • To summarize how Smad proteins regulate gene transcription in response to TGFbeta and how disruptions lead to cancer.

Main Methods:

  • Literature review of recent research findings.
  • Analysis of molecular mechanisms underlying TGFbeta signaling.
  • Examination of the role of Smad proteins in cell cycle regulation and tumor suppression.

Main Results:

  • TGFbeta signaling loss is implicated in the progression of pancreatic cancer.
  • Smad proteins are crucial mediators of TGFbeta's tumor suppressor activity by modulating cell cycle gene transcription.
  • Disruption of TGFbeta-Smad pathway regulation contributes to deregulated proliferation and tumor development.

Conclusions:

  • TGFbeta signaling is a critical tumor suppressor pathway frequently dysregulated in pancreatic cancer.
  • Understanding TGFbeta-Smad interactions is vital for developing targeted therapies for pancreatic cancer.
  • Restoring TGFbeta responsiveness or Smad function may offer therapeutic strategies against pancreatic cancer.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...